Skip to main content

Table 1 Patient demographics summarized for the overall population and by biopsy diagnosis

From: An expanded biomarker panel for the detection of prostate cancer from urine DNA

Variable

Cases (n = 42)

Controls (n = 52)

Age

 n (%)

42 (100.0%)

50 (96.2%)

 Median

66

64

 Mean (SD)

67.1 (7.1)

63.9 (7.6)

 Range

48–84

50–83

PSA

 n (%)

40 (95%)

51 (98.1%)

 Median

6.4

5.2

 Mean (SD)

7.1 (3.3)

5.6 (2.7)

 Range

3.26–18.92

0.63–14.9

Race

 Alaskan Native

1 (2.4%)

0 (0.0%)

 Asian

0 (0.0%)

1 (1.9%)

 Black

4 (9.5%)

5 (9.6%)

 Hispanic

1 (2.4%)

1 (1.9%)

 White

36 (85.7%)

44 (84.6%)

 Missing

0 (0.0%)

1 (1.9%)

Urine samples

 DRE and FV

28 (66.7%)

32 (61.5%)

 DRE only

10 (23.8%)

17 (32.7%)

 FV only

4 (9.5%)

3 (5.8%)

Gleason score

 n

39 (92.9%)

NA

 Mean (SD)

7.1 (1.3)

 

 ≤ 7

26 (61.9%)

 

 > 7

13 (30.9%)

 

 Missing

3 (7.1%)

 

Positive cores

 n

39 (92.9%)

NA

 Mean (SD)

4.2 (3.6)

 

 ≤ 3

19 (45.2%)

 

 > 3

20 (47.6%)

 

 Missing

3 (7.1%)

 
  1. The mean PSA for cases was calculated after excluding 2 outliers which were greater than 2X the highest remaining PSA value from cases. NA: not applicable